First-year progress in MD Anderson’s Moon Shots Program

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers....

AML and MDS Moon Shot Annual Report 2013

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 launched its Moon Shots Program, an ambitious and comprehensive action plan to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. Initial moon shot cancers are breast and ovarian; acute myeloid leukemia and myelodysplastic syndromes; chronic lymphocytic leukemia; lung; melanoma and prostate cancer. Guillermo Garcia-Manero, M.D., professor in MD Anderson's...

Acute myeloid leukemia (AML) - a life threatening cancer

submitted by: mdanderson

Acute myeloid leukemia (AML) occurs when too many immature blood cells are produced by the bone marrow. Anemia, infection and bleeding may result and become life threatening. Guillermo Garcia-Manero, M.D., professor in Leukemia at MD Anderson Cancer Center, explains the symptoms, diagnosis and treatment of Acute myeloid leukemia.

UT MD Anderson Cancer Center launches unprecedented Moon Shots Program to increase patient survival during the next decade

submitted by: mdanderson
Inspired by America’s drive a generation ago to put a man on the moon, MD Anderson’s Moon Shots Program is a highly-concentrated effort to rapidly and dramatically decrease suffering and death in several major cancers, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung; melanoma; prostate and two cancers linked at the molecular level: triple-negative breast and ovarian. Focused teams are building on new technology and...

Childhood Leukemia: Most Common Childhood Cancer

submitted by: mdanderson

Childhood leukemia is the most common childhood cancer with more than 3,500 children in the U.S. diagnosed each year. Patrick Zweidler-McKay, M.D., Ph.D., Assistant Professor at The University of Texas MD Anderson Cancer Center Children’s Cancer Hospital, talks about symptoms, diagnoses and treatment of this blood disease. Zweidler-McKay also discusses health problems that may occur decades after treatment and encourages long term follow-up doctor visits.

Cancer Drug Shortage Is Costing Lives

submitted by: mdanderson
Acute myelogenous leukemia (AML) is a fast-progressing cancer that typically takes a patient's life within two to three months if not treated quickly and properly. Cytarabine is the only known drug to affectively treat AML, having a survival rate of 40% to 50%. Without cytarabine, the survival rate is 0%. The number of drugs, including those used to treat cancer, that are in short supply within the United States has tripled since 2005. Hagop Kantarjian, M.D., chair of the Department of...